Among thyroglobulin elevation and negative iodine scintigraphy patient's subgroup, 9.45% could qualify for 177 Lu-DOTATATE and 12.16% for 177 Lu-PSMA-617. Four were eligible for both therapies. Given the lack of effective therapies, this subset of patients warrants consideration for radionuclide therapy exploration.
Keyphrases
- pet ct
- end stage renal disease
- positron emission tomography
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- magnetic resonance imaging
- magnetic resonance
- patient reported outcomes
- cancer therapy
- drug delivery
- phase iii
- bone marrow
- study protocol
- cell therapy
- contrast enhanced